Synergistic anticancer effects of camptothecin and sotorasib in KRAS-mutated pancreatic ductal adenocarcinoma

Synergistic anticancer effects of camptothecin and sotorasib in KRAS-mutated pancreatic ductal adenocarcinoma

BackgroundSotorasib (AMG510) is a first-in-class irreversible, covalent, and selective KRAS G12C inhibitor. However, in patients, acquired clinical resistance was observed within 1 year of its FDA approval. Researchers are exploring combination and repurposing strategies to help overcome this resist...

Full description

Saved in:

Bibliographic Details
Main Authors:	Prasanna Srinivasan Ramalingam, Gayathri Chellasamy, Md Sadique Hussain, Gothandam Kodiveri Muthukaliannan, Tajamul Hussain, Salman Alrokayan, Kyusik Yun, Janaki Ramaiah Mekala, Sivakumar Arumugam
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-07-01
Series:	Frontiers in Pharmacology
Subjects:	alkaloid camptothecin sotorasib KRAS mutation PDAC synergistic effect
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1635449/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Sotorasib resistance triggers epithelial-mesenchymal transition and activates AKT and P38-mediated signaling
by: Raquel Arantes Megid, et al.
Published: (2025-01-01)

KRAS G12C mutation in NSCLC in a small genetic center: insights into sotorasib therapy response potential
by: Metin Eser, et al.
Published: (2024-11-01)

Sotorasib Is Not Effective in a KRAS‐Mutated Patient With Brain Metastases From Lung Adenocarcinoma due to Multiple Gene Co‐Mutations
by: Takayuki Suetsugu, et al.
Published: (2025-05-01)

Unveiling reverse vaccinology and immunoinformatics toward Saint Louis encephalitis virus: a ray of hope for vaccine development
by: Prasanna Srinivasan Ramalingam, et al.
Published: (2025-05-01)

Synthesis and Insecticidal Activity of Novel Camptothecin Derivatives Containing Analogs of Chrysanthemic Acid Moieties
by: Li DENG, et al.
Published: (2014-06-01)

Molecular Docking and Pharmacological In Silico Evaluation of Camptothecin and Related Ligands as Promising HER2-Targeted Therapies for Breast Cancer
by: Elmer Joel Millan-Casarrubias, et al.
Published: (2025-03-01)

Redox-sensitive camptothecin prodrug: A promising drug delivery strategy with ultrahigh drug loading and tunable drug release
by: Shiwei Fu, et al.
Published: (2025-12-01)

Targeting KRAS‐mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2
by: Satoru Miyazaki, et al.
Published: (2025-02-01)

A dataset of transcriptomic effects of camptothecin treatment on early zebrafish embryosGene Expression Omnibus
by: Sergey V. Prykhozhij, et al.
Published: (2024-12-01)

Targeting USP47 enhances the efficacy of KRAS inhibitor in KRASG12C mutated non-small cell lung cancer by controlling deubiquitination of c-Myc
by: Hyungkyung Shin, et al.
Published: (2025-05-01)

Metabolic profiling of lung cancer cells with acquired resistance to sotorasib
by: ZOU Peichen, et al.
Published: (2025-02-01)

KRAS-mutated non-small cell lung cancer: new therapy strategies
by: K. K. Laktionov, et al.
Published: (2024-05-01)

Adagrasib in KRYSTAL-12 has Not Broken the KRAS G12C Enigma Code of the Unspoken 6-Month PFS Barrier in NSCLC
by: Lee AT, et al.
Published: (2024-12-01)

Dual inhibition of GTP-bound KRAS and mTOR in lung adenocarcinoma and squamous cell carcinoma harboring KRAS G12C
by: Masaoki Ito, et al.
Published: (2025-05-01)

Caspase mediated apoptosis induced by CPT@PLA micro-nanofibers in C2C12 cells: insights into probable mechanism
by: Touseef Amna
Published: (2025-06-01)

KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma
by: Mahmoud Yousef, et al.
Published: (2025-04-01)

Ultrasound-triggered drug release and cytotoxicity of microbubbles with diverse drug attributes
by: Chi-Fen Chuang, et al.
Published: (2025-01-01)

Adagrasib in the Treatment of KRAS p.G12C Positive Advanced NSCLC: Design, Development and Place in Therapy
by: Warnecke B, et al.
Published: (2024-12-01)

Aminoquinazolin-4(3H)-one derivatives as multitargeting therapeutics in Alzheimer's disease
by: Tajamul Hussain, et al.
Published: (2025-07-01)

KRAS and NRF2 drive metabolic reprogramming in pancreatic cancer cells: the influence of oxidative and nitrosative stress
by: Valentina Rapozzi, et al.
Published: (2025-06-01)

KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adenocarcinoma
by: Analia Meilerman Abuelafia, et al.
Published: (2025-07-01)

Correction: KRAS and NRF2 drive metabolic reprogramming in pancreatic cancer cells: the influence of oxidative and nitrosative stress
by: Valentina Rapozzi, et al.
Published: (2025-08-01)

Elevated KRAS protein level is associated with better survival in pancreatic cancer
by: S. M. Stålberg, et al.
Published: (2025-07-01)

Social media applications in biomedical research
by: Md Sadique Hussain, et al.
Published: (2024-07-01)

Smart Irrigation Technologies and Prospects for Enhancing Water Use Efficiency for Sustainable Agriculture
by: Awais Ali, et al.
Published: (2025-04-01)

Correction: Non-coding RNAs as key regulators in hepatitis B virus-related hepatocellular carcinoma
by: Prasanna Srinivasan Ramalingam, et al.
Published: (2025-07-01)

Non-coding RNAs as key regulators in hepatitis B virus-related hepatocellular carcinoma
by: Prasanna Srinivasan Ramalingam, et al.
Published: (2025-06-01)

COVID-19 Symptomatology from the Otorhinolaryngology Perspective: Survey from Tertiary Care Center
by: Raj Tajamul Hussain, et al.
Published: (2023-09-01)

Adult Pancreatoblastoma: Clinical Insights and Outcomes Compared to Pancreatic Ductal Adenocarcinoma (PDAC)
by: Han Yin, et al.
Published: (2024-08-01)

Efficacy of CRISPR-Cas9 gene editing for targeting KRAS mutations in pancreatic cancer: a systematic review
by: Hashim Talib Hashim, et al.
Published: (2025-04-01)

Combination of farnesyl-transferase inhibition with KRAS G12D targeting breaks down therapeutic resistance in pancreatic cancer
by: Eszter Molnár, et al.
Published: (2024-12-01)

CHAMP1 premature termination codon mutations found in individuals with intellectual disability cause a homologous recombination defect through haploinsufficiency
by: Yujiro Yoshizaki, et al.
Published: (2024-12-01)

Sotorasib resistance in KRAS G12C-mutant invasive mucinous adenocarcinoma with implications for VEGF-A
by: Hiraku Yanada, et al.
Published: (2025-05-01)

Membrane vesicles from Red Complex bacteria: key players in oral pathogenesis, immune disruption, systemic diseases, and therapeutic insights
by: Venkatramanan Mahendrarajan, et al.
Published: (2025-07-01)

Role and mechanism of action of nuclear receptor coactivator 4 in the development of acquired resis-tance to targeted inhibitors in pancreatic cancer with KRAS G12C mutation
by: CHANG Hao, WANG Ya'nan, LIU Shihai, WANG Jing
Published: (2025-08-01)

Dual inhibition of HERs and PD-1 counteract resistance in KRASG12C-mutant head and neck cancer
by: Ofra Novoplansky, et al.
Published: (2024-11-01)

PLAGL2 as a prognostic biomarker and an EMT-promoting factor in PDAC
by: Yan-Hui Yang, et al.
Published: (2025-07-01)

The comparison of IGFBP-5 expression level in Pancreatic ductal adenocarcinoma tumors and their normal adjacent tissues
by: Jafar Karim Ghate, et al.
Published: (2025-06-01)

Weighted gene co-expression network analysis reveals key stromal prognostic markers in pancreatic cancer
by: G. Mantini, et al.
Published: (2024-12-01)

Identification and characterization of tumor and stromal derived liquid biopsy analytes in pancreatic ductal adenocarcinoma
by: Julian Götze, et al.
Published: (2025-01-01)